Guilin Sanjin Pharmaceutical Co, a traditional Chinese medicine maker, saw strong earnings this year, according to its interim report, which the company released yesterday.
Guilin Sanjin, the first company to raise money from Shenzhen Stock Exchange market via an initial public offering (IPO) after the ban on new share issues was lifted last month, posted a net profit of about 159.98 million yuan ($23.42 million) in the first half, up 13.34 percent year-on-year.
The company reaped a revenue of 479.85 million yuan, up nine percent over the same period a year earlier.
In the first six months this year, the company's per-share earnings rose 11.43 percent to 0.39 yuan and its return on equity ratio reached 20.86 percent, up 4.48 percent year-on-year.
(Chinadaily.com.cn July 29, 2009)
